A post-hoc analysis of the REDEFINE 1 trial presented at The Menopause Society’s 2026 Annual Meeting reports that CagriSema, an investigational combination of semaglutide and cagrilintide, produced mean weight reductions of 23.1% to 26.7% in women across pre-, peri- and post-menopause and in hormone therapy users. The findings, based on 1,902 women with overweight or obesity treated for 68 weeks, arrive as Novo Nordisk awaits an FDA decision on the dual-agonist candidate anticipated in late 2026.
The result matters for the peptide therapy and research peptide industry because it extends the clinical narrative for multi-agonist peptides beyond glycemic control into weight management across reproductive life stages, a population that clinics and telehealth operators increasingly serve. It also sharpens questions about how investigational, approved and compounded peptide products are distinguished in practice, and about the supply and quality controls that surround any peptide-based therapy.
What the REDEFINE 1 post-hoc analysis actually found
The analysis evaluated 1,902 women aged 18 to 81 with overweight or obesity across four cohorts: pre-menopause, peri-menopause, post-menopause and hormone therapy (HT) use. Over 68 weeks, mean weight reductions were 26.7% in pre-menopause, 24.8% in peri-menopause, 23.1% in post-menopause and 25.6% with HT, according to the meeting poster data.
Between 91% and 95.1% of participants reached at least 10% weight loss, while 63.2% to 78.3% achieved at least a 20% reduction. Waist circumference decreased by 19.2 to 21.7 centimeters. Significant improvements occurred in blood pressure, fasting glucose and triglycerides regardless of reproductive stage or HT use, while cholesterol changes were variable.
The authors noted that weight reduction was numerically greater in pre-menopausal women than in peri- and post-menopausal women, and that a greater proportion of pre-menopausal participants reached at least 20% weight loss. However, no formal treatment-by-subgroup interaction testing was performed, so the between-group differences should not be read as statistically established.
Key numbers at a glance
| Measure | Result | Context |
|---|---|---|
| Population analyzed | 1,902 women, aged 18–81 | Post-hoc analysis of REDEFINE 1 |
| Treatment duration | 68 weeks | Mean weight reduction by cohort |
| Pre-menopause | 26.7% | Mean weight loss |
| Peri-menopause | 24.8% | Mean weight loss |
| Post-menopause | 23.1% | Mean weight loss |
| Hormone therapy use | 25.6% | Mean weight loss |
| ≥10% weight loss | 91%–95.1% | Across subgroups |
| ≥20% weight loss | 63.2%–78.3% | Across subgroups |
| Waist circumference | −19.2 to −21.7 cm | Reduction |
| Meta-analysis | 8 RCTs; 6,898 participants | Greater weight loss vs monotherapies and placebo |
| REDEFINE 4 | 23% vs 25.5% | CagriSema vs tirzepatide 15 mg; noninferiority not met |
Why it matters for peptide therapy and research peptide businesses
For peptide therapy clinics, medical spas and telehealth platforms, the data add a menopause-specific evidence layer to a category that has largely been discussed in general obesity terms. Clinics that counsel women on weight management may face more questions about dual- and multi-agonist peptides, even though CagriSema remains investigational and is not an approved treatment. The distinction between an investigational drug, an FDA-approved medicine, a compounded drug and a research-use-only peptide is central here: a research-use designation does not establish suitability, sterility, safety or authorization for human administration.
For research peptide suppliers and buyers, the news reinforces demand for rigorous identity, purity and batch documentation. A certificate of analysis reports specified analytical results for a material or batch; it does not independently establish clinical safety, efficacy, sterility for a particular use or regulatory approval. As interest in amylin and GLP-1 combinations grows, buyers may ask more often for LC-MS identity confirmation alongside HPLC purity data, because chromatographic purity and assay content measure different things.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence; visit PeptideDDP.com for the latest first-hand information and industry updates. For readers tracking the category, peptidescm is a useful reference point for supply-chain and industry context.
Research and market context beyond the poster
Supporting data cited in the coverage include a 52-week functional MRI substudy showing that CagriSema altered neural responses to high-calorie food cues in brain reward and craving centers, which the authors linked to reduced food noise and hunger. MRI substudies in type 2 diabetes also demonstrated reductions in ectopic fat around the liver and pancreas plus abdominal visceral fat loss. These mechanistic findings are attributed and do not by themselves establish clinical outcomes.
A systematic review and meta-analysis of 8 randomized trials involving 6,898 participants found that CagriSema achieved greater weight reductions than semaglutide monotherapy, cagrilintide monotherapy and placebo, with improvements in HbA1c, waist circumference and blood pressure. In the head-to-head phase 3 REDEFINE 4 trial of 809 participants, CagriSema produced 23% mean weight loss over 84 weeks but did not achieve noninferiority versus tirzepatide 15 mg, which achieved 25.5%.
Safety data described adverse events as predominantly gastrointestinal, including nausea and diarrhea, mostly mild to moderate and transient. A pooled meta-analysis found that serious adverse events did not significantly differ between CagriSema and active monotherapies or placebo, despite more frequent GI events. Pharmacists cited in the coverage also advise monitoring for potential lean muscle loss of 15% to 25% during rapid weight reduction and screening for vitamin D and B12 deficiencies; this is guidance-based and not a CagriSema-specific trial finding.
What comes next
An FDA decision on CagriSema is anticipated in late 2026, according to the coverage. Until then, the REDEFINE 1 post-hoc results remain subgroup data from a single trial and should be interpreted with the limits of post-hoc analysis in mind. Industry observers note that the menopause-specific framing may influence how clinics discuss weight management with women, but the available evidence does not yet establish that menopause stage modifies treatment response in a statistically meaningful way.
For the peptide supply chain, the more immediate watch items are manufacturing capacity for GLP-1 and amylin peptides, the analytical methods used to characterize combination products, and the documentation that clinics and distributors request when evaluating suppliers. Those operational questions will likely matter as much as the headline weight-loss figures.
FAQ
What is CagriSema?
CagriSema is an investigational combination of semaglutide, a GLP-1 receptor agonist, and cagrilintide, a long-acting amylin, developed by Novo Nordisk for diabetes and obesity. It is not an approved treatment.
How much weight loss did the REDEFINE 1 analysis show?
Mean weight reductions ranged from 23.1% to 26.7% across pre-, peri- and post-menopause and HT-use cohorts over 68 weeks, according to the post-hoc analysis presented at The Menopause Society’s 2026 Annual Meeting.
Did CagriSema beat tirzepatide?
No. In the REDEFINE 4 trial, CagriSema achieved 23% mean weight loss over 84 weeks versus 25.5% for tirzepatide 15 mg, and noninferiority was not met.
Is CagriSema FDA-approved?
Not yet. An FDA decision is anticipated in late 2026. Research peptides are for research use only and must not be described as approved treatments; prescription and medical supervision apply to approved therapies.
Comments